Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis

This article has no abstract
Epistemonikos ID: e4a55d1b436fbf2aa5c4c308d4e52a5b9d7a89ac
First added on: Jul 12, 2025